The mission of the Developmental Therapeutics Program, at the Alabama Center for Childhood Cancer and Blood Disorders, is to identify and develop new therapies for children and young adults with cancer. Our ultimate goal is to improve the cure rate of pediatric cancers while also decreasing immediate and long-term side effects experienced by children undergoing treatment. Patients referred to the Developmental Therapeutics Program typically have recurrent or refractory malignancies that have failed standard therapies. Other patients may be diagnosed with rare tumors for which no effective therapies have been established.

As one of only 21 institutions offering studies sponsored by the Children’s Oncology Group Phase 1 and Pilot Consortium, we are able to provide patients access to innovative therapies not widely available. The Developmental Therapeutics Program is also a member of the Sarcoma Alliance for Research through Collaboration (SARC), which undertakes clinical trials of sarcomas; such tumors, especially when metastatic or relapsed, are often exceptionally resistant to conventional treatments. Additionally, we work with the pharmaceutical industry and with the fertile scientific community at the University of Alabama at Birmingham (UAB).

Ongoing collaborations include bench to bedside clinical trials of promising new agents or combinations of agents to treat pediatric cancers including rhabdomyosarcoma, osteosarcoma, and neuroblastoma. By combining the innovation and expertise of the UAB Division of Pediatric Hematology-Oncology, Children’s of Alabama, and researchers from UAB and around the world, the Developmental Therapeutics Program offers cutting-edge therapies and state-of-the-art care while helping to advance the treatment of pediatric cancers for generations to come.

Stuart Cramer, DO
Director, Developmental Therapeutics
UAB Division of Pediatric Hematology-Oncology